Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Applied Therapeutics Inc (NQ: APLT )

2.700 -0.065 (-2.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 669,730
Open 2.750
Bid (Size) 2.670 (8)
Ask (Size) 2.730 (1)
Prev. Close 2.765
Today's Range 2.570 - 2.820
52wk Range 0.4995 - 2.900
Shares Outstanding 63,124,227
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Applied Therapeutics Inc. (NASDAQ: APLT) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network

Performance

YTD
+258.95%
+258.95%
1 Month
+84.93%
+84.93%
3 Month
+90.14%
+90.14%
6 Month
+221.39%
+221.39%
1 Year
+183.73%
+183.73%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports Second Quarter 2023 Financial Results
From Applied Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Applied Therapeutics Provides Regulatory Update on Galactosemia Program
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association
From Applied Therapeutics
Via GlobeNewswire
Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session
Via Benzinga
Applied Therapeutics to Present Data on AT-007 (Govorestat) Treatment in SORD Deficiency at the 2023 Annual Meeting of the Peripheral Nerve Society
From Applied Therapeutics
Via GlobeNewswire
Govorestat (AT-007) Receives Orphan Medicinal Product Designation from the EMA for Treatment of SORD Deficiency
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports First Quarter 2023 Financial Results
From Applied Therapeutics
Via GlobeNewswire
7 Hot Growth Stocks Poised to Triple in 2023
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why First Republic Bank Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Applied Therapeutics' Investigational Drug Shows Clinical Benefit In Rare Metabolic Disorder, Chalks Out FDA Submission Plans
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Applied Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
From Applied Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.